In digital health, progress is often confused with activity. A team builds a prototype, runs a demo, gets a pilot conversation, and assumes it is close to adoption. Then everything slows down. Funding becomes harder. Hospitals ask for evidence. Partners hesitate. The issue is usually not the idea. It is maturity.
Technology Readiness Levels (TRL) provide a simple way to describe maturity from early concepts to real-world deployment. More importantly, TRL forces a practical question: what have you proven, in what setting, and what uncertainty did you remove?
This matters because both funders and buyers make decisions based on risk. EU funding reviewers want to see that you understand where you are today and what needs to be proven during the project. Healthcare stakeholders want to see that you can move from “works on a laptop” to “works in real clinical workflows” and that you can measure impact, not only engagement.
In practice, TRL becomes useful when it is linked to evidence. Instead of saying “we are TRL4”, you show what you tested, who was involved, what outcomes were measured, and what the result implies for the next stage. This turns maturity into credibility.
A simple rule: if you cannot explain what changes between your current TRL and the next TRL in concrete proof terms, your roadmap is probably too vague. And vague roadmaps get rejected, delayed, or stuck in pilot mode.
Worthmed® supports teams by translating TRL into a clear proving plan, usually starting with a fast evidence benchmark, followed by data analysis or targeted pilots depending on the maturity gap.